Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects
of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Background Non-alcoholic fatty liver disease, or as recently proposed 'metabolic-associated
fatty liver disease'(MAFLD), is characterized by pathological accumulation of triglycerides …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …

Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of
the world's adult population. Several cohort studies have consistently documented that …